Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

  • STATUS
    Recruiting
  • End date
    Mar 25, 2023
  • participants needed
    248
  • sponsor
    Karyopharm Therapeutics Inc
Updated on 25 January 2021
platelet count
renal function
cancer
remission
maintenance therapy
metastasis
neutrophil count
liver metastasis
adjuvant therapy
uterine disease
recurrent disease
adjuvant chemotherapy
recurrent endometrial cancer
carcinosarcoma
uterine carcinosarcoma

Summary

This is a prospective, multicenter, double-blind, placebo-controlled, randomized Phase 3 study. The purpose of the study is to obtain evidence of efficacy for maintenance selinexor in participants with advanced or recurrent endometrial cancer. Participants with primary stage IV or recurrent disease who are in partial or complete response after having completed a single line of at least 12 weeks of taxane-platinum combo therapy will be randomized in a 2:1 manner to maintenance therapy with 80 milligram (mg) with selinexor once weekly (QW) or placebo until progression.

Details
Condition Endometrial Carcinoma, Uterine Cancer, Endometrial Cancer
Treatment Placebo, Selinexor, Matching placebo for selinexor
Clinical Study IdentifierNCT03555422
SponsorKaryopharm Therapeutics Inc
Last Modified on25 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Are you female?
Do you have any of these conditions: Endometrial Cancer or Endometrial Carcinoma or Uterine Cancer?
Do you have any of these conditions: Endometrial Cancer or Uterine Cancer or Endometrial Carcinoma?
Female, at least 18 years of age at the time of informed consent
Histological confirmed endometrial cancer of the endometrioid, serous, or undifferentiated type. Carcinosarcoma of the uterus is also allowed
Completed a single line of at least 12 weeks of taxane-platinum combination therapy (not including adjuvant or neoadjuvant therapy), and achieved partial remission (PR) or complete remission (CR) according to RECIST version 1.1 for
Primary Stage IV disease, defined as
had a primary or later debulking surgery during first-line taxane-platinum therapy with R0 resection (R0 resection indicates a macroscopic complete resection of all visible tumor) and achieved CR after at least 12 weeks taxane-platinum chemotherapy, OR
had a primary or later debulking surgery during first-line taxane-platinum therapy with R1 resection (R1 resection indicates incomplete removal of all macroscopic disease,) and achieved PR or CR after at least 12 weeks taxane-platinum chemotherapy, OR
had no surgery and achieved PR or CR after at least 12 weeks taxane-platinumchemotherapy
OR
At first relapse (i.e., relapse after primary therapy including surgery and/or chemotherapy therapy for Stage I-IV disease), defined as
had Stage I-III disease at diagnosis and received at initial diagnosis adjuvant chemotherapy and relapsed later. Participants should have PR or CR after at least 12 weeks of taxane-platinum chemotherapy compared with the start of this chemotherapy at the time of relapse, OR
had Stage I-III disease at diagnosis and did not receive adjuvant chemotherapy at initial diagnosis and relapsed later. Participants should have PR or CR after at least 12 weeks of taxane-platinum chemotherapy compared with the start of this chemotherapy at the time of relapse, OR
had Stage IV disease at diagnosis and received initially chemotherapy with or without surgery and relapsed later. At the time of relapse, participants should have PR or CR after at least 12 weeks of taxane-platinum chemotherapy compared with the start of this chemotherapy at the time of relapse
Participants that required their chemotherapy dose held during the 12-week
therapy may be considered if they meet the other criteria above and achieve PR
or CR per RECIST V1.1
Must be able to initiate study drug 5 to 8 weeks after completion of their final dose of chemotherapy
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Participants must have adequate bone marrow function and organ function within 2 weeks before starting study drug as defined by the following laboratory criteria
Hepatic function: total bilirubin up to 1.5 _upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to () 2.5_ ULN in participants without liver metastasis. For participants with known liver involvement of their tumor: AST and ALT 5ULN
Hematopoetic function: Absolute neutrophil count (ANC) greater than or equal to () 1.5 _10^9/L; platelet count 100_ 10^9 per liter (/L); hemoglobin 9.0 gram per deciliter (g/dL)
Renal function: estimated creatinine clearance (CrCl) of 20 milliliter per minute (mL/min), calculated using the Cockroft Gault formula
In the opinion of the Investigator, the participant must
Have a life expectancy of at least 12 weeks, and
Be fit to receive experimental therapy
Premenopausal females of childbearing potential must have a negative pregnancy test (serum -human chorionic gonadotropin test) prior to the first dose of study drug. Female participants of childbearing potential must agree to use highly effective methods of contraception throughout the study and for 1 week following the last dose of study drug
Written informed consent in accordance with federal, local, and institutional guidelines. The participant must provide informed consent prior to the first Screening procedure

Exclusion Criteria

Has any sarcomas, small cell carcinoma with neuroendocrine differentiation, or clear cell carcinomas
Received a blood or platelet transfusion during 4 weeks prior to randomization
Being treated with a concurrent cancer therapy
Previous treatment with an exportin 1 (XPO1) inhibitor
Previous treatment with anti- programmed cell death protein 1 (PD-1) or anti-programmed cell death ligand-1 (PD-L1) immunotherapy (e.g., pembrolizumab)
Concurrent treatment with an investigational agent or participation in another clinical trial
Participants who received any systemic anticancer therapy including investigational agents or radiation 3 weeks (or 5 half-lives of the drug [whichever is shorter]) prior to cycle 1 day 1 (C1D1). Palliative radiotherapy may be permitted for symptomatic control of pain from bone metastases in extremities, provided that the radiotherapy does not involve target lesions, and the reason for the radiotherapy does not reflect progressive disease (PD)
Major injuries or surgery within 14 days prior to C1D1 and/or planned surgery during the on-treatment study period
Previous malignant disease, except participants with other malignant disease, for which the participant has been disease-free for at least 3 years. Concurrent other malignant disease except for curatively treated carcinoma in situ of the cervix or basal cell carcinoma of the skin
Any life-threatening illness, medical condition or organ system dysfunction, which, in the investigator's opinion, could compromise the participant's safety or compliance with the protocol
Known contraindications to selinexor
Known uncontrolled hypersensitivity to the investigational drug, or to its excipients
Radiotherapy to the target lesion within the past 3 months prior to baseline imaging
Persistent Grade 3 or 4 toxicity from previous chemotherapy and/or radiotherapy, with the exception of alopecia
Active brain metastases (e.g., stable for <8 weeks, no adequate previous treatment with radiotherapy and/or surgery, symptomatic, requiring treatment with anti-convulsants. Corticoid therapy is allowed if administered as stable dose for at least 1 month before randomization)
Known unstable cardiovascular function
Symptomatic ischemia, or
Uncontrolled clinically significant conduction abnormalities (i.e., ventricular tachycardia on anti-arrhythmia are excluded; 1st degree atrioventricular block or asymptomatic left anterior fascicular block /right bundle branch block will not be excluded), or
Congestive heart failure of New York Heart Association Class 3, or
Myocardial infarction within 3 months
Females who are pregnant or actively breastfeeding
Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to first dose; however, prophylactic use of these agents is acceptable even if parenteral
Active hepatitis C and/or B infection
Participants unable to swallow tablets, participants with malabsorption syndrome, or any other gastrointestinal (GI) disease or GI dysfunction that could interfere with absorption of study drug. A history of bowel obstruction requiring a nasogastric tube or intravenous infusion during the past 2 months is not allowed (except when this obstruction is caused by surgery or other non-malignant causes)
Psychiatric illness or substance use that would prevent the participant from giving informed consent or being compliant with the study procedures
Participants unwilling or unable to comply with the protocol
Persons who have been committed to an institution by official or judicial order
Participants with dependency on the Sponsor, Investigator or study site
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note